Summit Therapeutics plc (SMMT): Price and Financial Metrics


Summit Therapeutics plc (SMMT): $6.82

-0.29 (-4.08%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

SMMT Stock Summary

  • The ratio of debt to operating expenses for Summit Therapeutics plc is higher than it is for about only 0.42% of US stocks.
  • With a year-over-year growth in debt of -100%, Summit Therapeutics plc's debt growth rate surpasses merely 0% of about US stocks.
  • Revenue growth over the past 12 months for Summit Therapeutics plc comes in at 1,893.29%, a number that bests 99.56% of the US stocks we're tracking.
  • If you're looking for stocks that are quantitatively similar to Summit Therapeutics plc, a group of peers worth examining would be VYGR, ANAB, CRBP, CARA, and NVAX.
  • Visit SMMT's SEC page to see the company's official filings. To visit the company's web site, go to www.summitplc.com.

SMMT Stock Price Chart Interactive Chart >

Price chart for SMMT

SMMT Price/Volume Stats

Current price $6.82 52-week high $12.30
Prev. close $7.11 52-week low $2.91
Day low $6.81 Volume 184,400
Day high $7.28 Avg. volume 226,230
50-day MA $6.51 Dividend yield N/A
200-day MA $5.37 Market Cap 663.21M

Summit Therapeutics plc (SMMT) Company Bio


Summit Therapeutics plc operates as a biopharmaceutical company primarily in the United Kingdom and the Unites States. It focuses on the discovery, development, and commercialization of novel medicines to treat the Duchenne Muscular Dystrophy (DMD), a fatal muscle wasting disease; and infections caused by Clostridium difficile bacteria (CDI). The company was founded in 2003 and is based in Abingdon, England.


SMMT Latest News Stream


Event/Time News Detail
Loading, please wait...

SMMT Latest Social Stream


Loading social stream, please wait...

View Full SMMT Social Stream

Latest SMMT News From Around the Web

Below are the latest news stories about Summit Therapeutics Inc that investors may wish to consider to help them evaluate SMMT as an investment opportunity.

Summit Therapeutics set to join Russell 3000 Index

Cambridge, MA, June 08, 2021 (GLOBE NEWSWIRE) -- Summit Therapeutics Inc. (NASDAQ: SMMT) is set to join the broad-market Russell 3000 Index at the conclusion of the 2021 Russell indexes annual reconstitution, effective after the US markets open on June 28, according to a preliminary list of additions posted by FTSE Russell. Annual Russell indexes reconstitution captures the 4,000 largest US stocks

Wallstreet:Online | June 8, 2021

Crestone Joins Antimicrobials Working Group

The Antimicrobials Working Group (AWG) announced today the addition of Crestone, Inc. (Crestone) to its coalition of companies with the mission to combat drug resistant infections and spur life-saving innovations. This new addition brings AWG's membership to 12 antimicrobial drug companies.

Yahoo | June 8, 2021

Summit Therapeutics set to join Russell 3000® Index

Summit Therapeutics Inc. is set to join the broad-market Russell 3000® Index at the conclusion of the 2021 Russell indexes annual reconstitution, effective after the US markets open on June 28, according to a preliminary list of additions posted by FTSE Russell.

BioSpace | June 7, 2021

Summit Therapeutics’ Upcoming Annual Shareholders’ Meeting

Cambridge, MA, June 03, 2021 (GLOBE NEWSWIRE) -- Summit Therapeutics Inc. (NASDAQ: SMMT) invites our shareholders and other interested parties to attend our Company’s Annual Shareholders’ Meeting, which will be held virtually on Wednesday, June 16, 2021, at 1:00 pm Eastern Time. We look forward to your attendance at this meeting. A link to the event can be found here: www.virtualshareholdermeeting.com/SMMT2021. About Summit TherapeuticsSummit Therapeutics, empowered by its Discuva Platform, the

Yahoo | June 3, 2021

Summit Therapeutics Unveils Preclinical Candidate For Multidrug-Resistant Infections

Summit Therapeutics Inc (NASDAQ: SMMT ) has selected a new preclinical candidate , SMT026738 (SMT-738), for development against multidrug-resistant infections, specifically carbapenem-resistant Enterobacteriaceae (CRE) infections. Simultaneously, Summit has received an Full story available on Benzinga.com

Benzinga | May 18, 2021

Read More 'SMMT' Stories Here

SMMT Price Returns

1-mo 26.06%
3-mo 6.56%
6-mo 20.49%
1-year 95.42%
3-year -45.92%
5-year -18.32%
YTD 45.11%
2020 193.75%
2019 39.13%
2018 -89.62%
2017 29.44%
2016 -25.57%

Continue Researching SMMT

Here are a few links from around the web to help you further your research on Summit Therapeutics plc's stock as an investment opportunity:

Summit Therapeutics plc (SMMT) Stock Price | Nasdaq
Summit Therapeutics plc (SMMT) Stock Quote, History and News - Yahoo Finance
Summit Therapeutics plc (SMMT) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.7994 seconds.